127561-33-5Relevant articles and documents
Supported iron catalysts for Michael addition reactions
Ye, Rong,Faucher, Franco F.,Somorjai, Gabor A.
, p. 65 - 71 (2018/02/13)
Heterogeneous catalysts have been widely used for chemical transformations and offer easy product separation in addition to their high activity. Iron is an earth-abundant metal, but it has not been studied thoroughly as heterogeneous catalysts for organic
The discovery of novel cyclohexylamide CCR2 antagonists
Lanter, James C.,Markotan, Thomas P.,Zhang, Xuqing,Subasinghe, Nalin,Kang, Fu-An,Hou, Cuifen,Singer, Monica,Opas, Evan,McKenney, Sandra,Crysler, Carl,Johnson, Dana,Molloy, Christopher J.,Sui, Zhihua
scheme or table, p. 7496 - 7501 (2012/02/13)
As a result of further SAR studies on a piperidinyl piperidine scaffold, we report the discovery of compound 44, a potent, orally bioavailable CCR2 antagonist. While having some in vitro hERG activity, this molecule was clean in an in vivo model of QT pro
α1b-adrenergic receptor antagonists
-
Page/Page column 78, (2010/11/30)
There are provided compounds represented by the general formula (I): [wherein Ar is indole etc., R1is hydrogen etc., B is bond, or B—N—R1forms a ring structure and is piperidine etc., n is 0, 1, etc., A is trimethylene, butylene, etc., Q is piperidine, isoindoline, etc.], or pharmacologically acceptable acid addition salts thereof, and α1B adrenoceptor antagonists composed of these substances. The invented compounds are antagonists having high affinity for α1B adrenoceptor and are useful as pharmaceutical agents for use in prophylaxis/therapy of diseases (e.g., hypertension) in which α1B adrenoceptor is involved or as pharmacological tools for elucidation of physiological activities mediated by α1B adrenoceptor.
